FB-825 is under clinical development by Oneness Biotech and currently in Phase I for Allergic Rhinitis. According to GlobalData, Phase I drugs for Allergic Rhinitis have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-825’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FB-825 overview

FB-825 is under development for the treatment of allergic asthma, atopic dermatitis, allergic rhinitis and hyperimmunoglobulin E syndrome. It is administered through intravenous route. FB-825 is a humanized monoclonal antibody that targets to the specific CemX domain and kills the membrane IgE positive B lymphocytes. It is administered by intravenous route. It was under development for the treatment of food allergy.

Oneness Biotech overview

Oneness Biotech is a biopharmaceutical company. The company’s product pipeline comprises ON101 against diabetic foot ulcers, FB825 for atopic dermatitis and allergic asthma, FB704A against severe asthma, OB318 against cancer and FB918 against asthma. It offers products in the therapeutic areas of dermatology, immunology and infectious diseases, among others. Oneness Biotech is headquartered in Taipei, Taiwan.

For a complete picture of FB-825’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.